{
  "url": "https://struct.news/briefs/veevas-supplier-is-also-building-a-rival",
  "title": "Veeva’s Supplier Is Also Building a Rival",
  "summary": "Veeva buys Salesforce’s platform for Veeva CRM, sells software to major drugmakers, and faces Salesforce alongside a Salesforce-IQVIA partnership.",
  "published_at": "2026-08-06T23:48:32.825514+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Veeva Systems Inc.",
    "ticker": "VEEV",
    "cik": null,
    "sector": "Healthcare",
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "CRM",
      "value": "CRM",
      "display": "CRM",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    },
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "LLY",
      "value": "LLY",
      "display": "LLY",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    },
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "GILD",
      "value": "GILD",
      "display": "GILD",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    },
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "IQV",
      "value": "IQV",
      "display": "IQV",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    },
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "ORCL",
      "value": "ORCL",
      "display": "ORCL",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    },
    {
      "group": "Veeva’s disclosed relationship map",
      "label": "HON",
      "value": "HON",
      "display": "HON",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-06"
      }
    }
  ],
  "watch_next": [
    {
      "type": "pricing",
      "statement": "Zepbound demand is driving U.S. growth, while lower realized prices, including cash-pay reductions, are offsetting part of the increase.",
      "importance": "high",
      "evidence": "Revenue of Zepbound increased 44 percent and 58 percent in the U.S. during the three and six months ended June 30, 2026, respectively, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash-pay prices.",
      "source_date": "2026-08-05"
    },
    {
      "type": "regulation",
      "statement": "A routine FDA inspection at a CMO resulted in a pending '61' inspection classification, prompting an amendment to the vutrisiran submission and delaying the PDUFA action date and NDA approval.",
      "importance": "high",
      "evidence": "For example, due to a routine inspection by the FDA at a CMO facility that resulted in a pending 61 Table of Contents inspection classification, we amended our regulatory submission for vutrisiran for the treatment of hATTR-PN in adults, which delayed our PDUFA action date and AMVUTTRA’s initial NDA approval with the FDA.",
      "source_date": "2026-07-30"
    },
    {
      "type": "product_pipeline",
      "statement": "Monitor R&D expense changes tied to investments in compute capacity, AI talent, and data supporting product development.",
      "importance": "medium",
      "evidence": "Research and development expenses increased $3.1 billion or 9% driven by continued investments in compute capacity, AI talent, and data to support product development that benefits the entire portfolio, as well as impairment and other related expenses in our XBOX business.",
      "source_date": "2026-07-29"
    },
    {
      "type": "interest_rates",
      "statement": "Interest expense increased due to financing costs related to the Bridge Credit Agreement through the Avadel closing and interest on the Facilities.",
      "importance": "medium",
      "evidence": "The change in net loss of $175.5 million during the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, was primarily due to increases in total operating expenses and interest expense of $328.5 million and $46.8 million, respectively, primarily related to the Avadel Acquisition.",
      "source_date": "2026-07-28"
    }
  ],
  "related_tickers": [
    "ALKS",
    "ALNY",
    "CRM",
    "GILD",
    "HON",
    "IQV",
    "LLY",
    "MRK",
    "MSFT",
    "ORCL",
    "VEEV"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}